Watson David O., an insider at Apellis Pharmaceuticals Inc (APLS), sold 103,730 shares of the company on December 15, 2025, at a price of $24.49 per share, resulting in a total transaction value of $2.54 million. Following this sale, he retains 103,730 shares in the company.
Apellis Pharmaceuticals, headquartered in Waltham, Massachusetts, is a commercial-stage biopharmaceutical firm focused on developing novel therapeutic compounds to address diseases with high unmet needs. The company, which employs approximately 705 full-time staff, went public on November 9, 2017. Its flagship products include SYFOVRE, an approved treatment for geographic atrophy secondary to age-related macular degeneration, and EMPAVELI, designed for paroxysmal nocturnal hemoglobinuria. The company also markets systemic pegcetacoplan under the trade name Aspaveli in various jurisdictions.
Insider selling can occur for a variety of reasons, including diversification, tax planning, or personal financial needs. While significant insider sales may draw attention, routine transactions do not necessarily reflect negative sentiment toward the company. Investors are encouraged to consider insider activity as one aspect of their overall analysis, integrating it with other fundamental and technical indicators.
Insider transactions are required to be reported to the SEC, providing insights into the actions of company executives and board members. However, it is crucial for investors to examine patterns of insider activity over time and across multiple insiders rather than focusing on isolated transactions.
As of December 18, 2025, Apellis Pharmaceuticals holds a market capitalization of $3.1 billion, with a P/E ratio of 68.85 and an EPS of 0.30. The company is set to report its earnings on July 29, 2026, with an estimated EPS of $-0.33 and expected revenue of $214.0 million.